Cognition Therapeutics, Inc.
CGTX
$1.80
$0.1911.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 4.21% | -16.46% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -54.39% | 1.47% | |||
| Operating Income | 54.39% | -1.47% | |||
| Income Before Tax | 26.79% | 20.59% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 26.79% | 20.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 26.79% | 20.59% | |||
| EBIT | 54.39% | -1.47% | |||
| EBITDA | 54.45% | -1.55% | |||
| EPS Basic | 40.21% | 22.96% | |||
| Normalized Basic EPS | 40.24% | 22.87% | |||
| EPS Diluted | 42.55% | 21.43% | |||
| Normalized Diluted EPS | 40.24% | 22.87% | |||
| Average Basic Shares Outstanding | 22.39% | 3.01% | |||
| Average Diluted Shares Outstanding | 22.39% | 3.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||